SCHEMBL760861

SCHEMBL760861

C[Si](C)(C)c1ccc(N(c2ccc(-c3ccccc3)cc2)c2ccc3c(-c4ccccc4)c4cc(N(c5ccc(-c6ccccc6)cc5)c5ccc([Si](C)(C)C)cc5)ccc4c(-c4ccccc4)c3c2)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.33
TDP1 Q9NUW8 2/20 0.32
MEN1 O00255 1/20 0.32
THRB P10828 1/20 0.32
RECQL P46063 1/20 0.32
BLM P54132 1/20 0.32
KMT2A Q03164 1/20 0.32
PTAFR P25105 1/20 0.31
ESR1 P03372 2/20 0.31
ESR2 Q92731 2/20 0.31
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
MAPT P10636 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
TRIM58 Q8NG06 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14516040 1.00 ACHE (0.33) ACHETDP1MEN1THRBRECQL
SCHEMBL14516043 1.00 ACHE (0.33) ACHETDP1MEN1THRBRECQL
SCHEMBL760840 0.99 TDP1 (0.33) ACHETDP1MEN1THRBRECQL
SCHEMBL14515982 0.97 TDP1 (0.33) ACHETDP1MEN1THRBRECQL
SCHEMBL762127 0.92 PTAFR (0.33) ACHETDP1MEN1THRBRECQL
SCHEMBL14516041 0.91 PTGES (0.37)
SCHEMBL762476 0.91 ESR1 (0.36) MEN1KMT2AESR1ESR2KDM4E
SCHEMBL6123583 0.91 ACHE (0.39) ACHETDP1MEN1RECQLKMT2A
SCHEMBL14516022 0.91 NPC1 (0.32) TDP1MEN1KMT2APTAFRKDM4E
SCHEMBL761300 0.90 CYP1A2 (0.36) MEN1KMT2AESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902013-B1 NOVEL ANTHRACENE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND ORGANIC ELECTRONIC LIGHT EMITTING DEVICE USING THE SAME LG CHEMICAL LTD (KR) 2016-06-01 EP disclosed
US-8647753-B2 Organic electroluminescence device LG DISPLAY CO., LTD. (KR) 2014-02-11 US disclosed
US-8647753-B2 Organic electroluminescence device LG DISPLAY CO., LTD. (KR) 2014-02-11 US disclosed
US-8137823-B2 Anthracene derivatives, process for preparation thereof, and organic electronic light emitting device using the same LG CHEM, LTD. (KR) 2012-03-20 US disclosed
US-20090079334-A1 Novel Anthracene Derivatives, Process for Preparation Thereof, and Organic Electronic Light Emitting Device Using the Same LG CHEM, LTD. (KR) 2009-03-26 US disclosed
WO-2007105917-A1 NOVEL ANTHRACENE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND ORGANIC ELECTRONIC LIGHT EMITTING DEVICE USING THE SAME LG CHEM, LTD. (KR) 2007-09-20 WO disclosed
US-20070087222-A1 Organic electroluminescence device LG DISPLAY CO., LTD. (KR) 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090079334-A1 Novel Anthracene Derivatives, Process for Preparation Thereof, and Organic Electronic Light Emitting Device Using the Same XPOT, ALAD, APRT ACHE 650/4885TDP1 2558/4885MEN1 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.